Osteopenia and Osteoporosis Bradley K. Harrison, MD.

Slides:



Advertisements
Similar presentations
New Dimensions and Landmark Advances in Osteoporosis Management Felicia Cosman, MD Professor of Clinical Medicine Columbia University New York, NY Osteoporosis.
Advertisements

Osteoporosis 9 th January 2013 Dr Julian Tomkinson.
MENOPAUSE CURRICULUM SLIDE SET. What is menopause? Menopause is a normal, natural event, defined as the final menstrual period (FMP), confirmed after.
Osteoporosis Dr. Aisha Sheikh FCPS (Pak), Fellowship Diabetes/Endocrinology (AKUH), PG Dip Diab (UK) Consultant Endocrinologist.
A progressive bone disease characterized by decrease bone mass decreased bone density increased fracture risk Dr Gaurav Rathore MS Ortho, MCh Ortho, FRCS.
The FRAX tool for Osteoporosis Should all GP’s be calculating the Frax score prior to treatment Dr Sanjeev Patel Consultant Physician & Senior Lecturer.
Update on Osteoporosis Dr Terence O’Neill Consultant Rheumatologist.
Osteoporosis Wang Ying Department of Rehabilitation Medicine Renji Hospital, Jiaotong University.
WHO Osteoporosis Definition (1996)
Osteoporosis Created by: Tricia Fleming, University of Kansas Dietetic Intern Tammy Beason, MS, RD, Nutrition Education Specialist, Family Nutrition Education.
An Inpatient Topic? July 2006
Osteoporosis Bobby Parker.
Osteoporosis Lucy Cowdrey 4 th November What is it?
Bones, Calcium, and Osteoporosis. Bone Bone is living, constantly remodeled Reservoir of Calcium – Calcium levels of blood take precedence over bone levels.
OSC Recommendations for Bone Mineral Density Reporting Slides prepared by Kerry Siminoski, MD, FRCPC William Leslie, M.Sc., MD,
Osteoporosis Dr. Lauren Phillips Sugar Land Women’s Health.
Bone Health and Osteoporosis
Osteoporosis UBC Internal Medicine Program Dr. Mark Fok Dr. Maria Ashley.
Bone Mineral Density Testing March 29, Introduction Osteoporosis is a systemic skeletal disorder characterized by decreased bone mass and deterioration.
Fall Prevention subtitle.
UNDERSTANDING OSTEOPOROSIS Stephen L. Kates, MD Hansj ӧ rg Wyss Professor of Orthopaedic Surgery Department of Orthopedics and Rehabilitation Associate.
Osteoporosis Osteoporosis is defined as a loss of bone mass or bone mineral density characterized by height reduction, fractures, back/neck pain, and stooped.
Osteoporosis Let’s Work Together to Get Bone Healthy!
BONE HEALTH AFTER BREAST CANCER Studies and Recommendations April 30, 2012.
Osteoporosis Rajesh Kataria, D.O.. Osteoporosis “…is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of.
OSTEOPOROSIS Prof. Dr. Ülkü Akarırmak. Metabolic Bone Diseases Osteosclerosis Osteolysis Osteoporosis is the most common metabolic bone disease.
OSTEOPOROSIS 06/25/12 José L. González, PGY3. Definition  Reduction in bone strength  increase risk of fx  T-score: < -2.5 SDs  T-score: 30 yo, matched.
Osteoporosis and Fractures Are Common, and Becoming More So
Clinical manifestations and diagnosis of osteoporosis.
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
Osteoporosis Awareness and Prevention Lunch n Learn Series May 2007.
Osteoporosis Dr. Faik Altıntaş Yeditepe Üniversitesi Tıp Fakültesi
1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium... 1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium...
Osteoporosis Management: Clinical scenario
Osteoporosis.
Glucocorticoid-Induced Osteoporosis (GIO) Nguyen Thy Khue, MD, PhD Department of Endocrinology, HoChiMinh City University of Medicine and Pharmacy.
Fracture risk assessment
A Look at Osteoporosis Screening Guidelines Cynthia Phelan PGY
Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :
Aging Q3 ACOVE #9 Osteoporosis Jay Brzezinski, MD Medical University of South Carolina 2011.
Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.
Osteoporosis: Measuring the Problem
FDA’s Osteoporosis Guidance Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drugs Eric Colman, MD September 25, 2002.
Alimohammad Fatemi Assistant Professor of Rheumatology 1.
 Glucocorticoids  Excessive thyroid hormone  Diuretics: Furosemide  Cyclosporine, methotrexate, tacrolimus  Seizure medications: Phenytoin, phenobarbital.
COMMON LIFESTYLE DISEASES: OSTEOPOROSIS
Bones Part 4 DR. T Jim, Tyler and Matt.
Definition Definition Osteoporosis:A condition of skeletal fragility characterized by reduced bone mass and microarchitectural deterioration of.
Osteoporosis By, Shelby, Eduardo, and Varshini. What is Osteoporosis? Osteoporosis means porous bone It is a disease associated with progressive bone.
Osteoporosis In Thalassemia Dr Tarek Jawad INT 555.
Welcome To Our Presentation
OSTEOPOROSIS. Characteristics of osteoporosis include a reduction of bone density and a change in bone structure, both of which increase susceptibility.
Chapter 47 Assessing Fracture Risk: Who Should Be Screened? © American Society for Bone and Mineral Research Contributed by John Schousboe, Brent Taylor,
NICE, FRAX & NOGG VTS meeting Jonathan Day 7 th April 2010.
Moji Saberin-Williams, M.D. Paoli Hospital Obstetrician/Gynecologist
Osteoporosis Dr Janet Horner Leeds Teaching Hospitals NHS Trust.
Chapter ?? 23 Osteoporosis Nichols and Pavlovic C H A P T E R.
OSTEOPOROSIS Dr Annie Cooper Consultant Rheumatologist Royal Hampshire County Hospital Winchester.
 Osteoporosis means "porous bones," causes bones to become weak and brittle – so brittle that even mild stresses like bending over, lifting a vacuum.
Osteoporosis Vinod Kurup, MD December 22nd, 2006 CC-BY-SA.
Osteoporosis and Bone Health
Post Menopausal Osteoporosis
Osteoporosis Definition
OSTEOPOROSIS. OSTEOPOROSIS Osteoporosis Osteoporosis affects both men and women. Its prevalence increases with age, and it is particularly common in.
Deciding on Pharmacological Treatment Post Fracture
Deciding on Pharmacological Treatment Post Fracture
(Relates to Chapter 64, “Focous on osteoperosis ,” in the textbook)
Reporting the Results of DXA Scan
Consultant Rheumatologist Imperial College Healthcare
Presentation transcript:

Osteopenia and Osteoporosis Bradley K. Harrison, MD

Who should we screen? Women aged ≥ 65 Postmenopausal women with fragility fracture Women on or starting glucocorticoid therapy Younger postmenopausal women with risk factors YES Not addressedYES Not addressedYES At age 60 if: Weight < 154 lb Estrogen deficient No recommendations for or against bone density testing in women <60 year Weight < 127 lb Early menopause Smoking Family history of fracture Medical causes USPSTF*NOF*/AACE* *USPSTF: US Preventative Services Task Force *NOF: National Osteoporosis Foundation *AACE: American Association of Clinical Endocrinologists

Evaluating Patients for Screening  Low bone mass at any skeletal site is associated with a substantially increased risk of fracture Height loss: vertebral fractures are diagnostic of skeletal fragility  Advancing age  Low body weight  Maternal history of osteoporosis  Smoking  Early menopause  Corticosteroid usage  The presence of a previous fracture!

What is a DEXA?  Dual-energy x-ray absorptiometry Originally intended for use in epidemiologic and public health studies; only applicable to hip, spine, and forearm measurements Painless, quick, safe, accurate, precise, relatively inexpensive way to assess bone mineral density Hip and Spine: 2 most common sites of osteoporotic fractures The World Health Organization (WHO) has established diagnostic criteria for osteoporosis Absolute readings vary among different manufacturer’s DEXA scanners, the patient’s results are compared with the mean BMD of a normal population on the same equipment

What is a T-score?  T Score Number of standard deviations the bone-mineral-density (BMD) measurement is above or below the young-normal mean bone density  Diagnose osteoporosis and to estimate fracture risk  Z Score Used to compare the patient's BMD to a population of peers, is calculated by subtracting the mean BMD of an age-, ethnicity-, and sex-matched reference population from the patient's BMD and dividing by the SD of the reference population  Indicate if BMD is lower than expected for the patient at a given age; signals need for earlier intervention; unsuspected conditions

T-scores…  Spine: aggregate of all lumbar vertebrae (L1-L4) are used  Hip: 3 sites for diagnosis (femoral neck, trochanter, total hip)  The lowest T-score is used to establish the patient’s diagnosis  -2.5: the point at which the proportion of white women older than 50 years with osteoporosis diagnosed by bone density (30%) nearly matches the % of women older than 50 years who will experience a fracture (spine, hip, forearm) in their lifetime (40%)  Between -1.0 and -2.5 indicative of low bone density…osteopenia

The WHO Criteria ≥ -1.0Normal -2.5Osteopenia ≤ -2.5Osteoporosis ≤ -2.5 or lower + fracturesSevere Osteoporosis T-ScoresDiagnosis

The Clinical Problem  Osteoporosis Progressive disease of increased skeletal fragility accompanied by low bone mineral density and microarchitectural deterioration  Spectrum: asymptomatic bone loss to hip fracture ($40K) Defined: T score for bone mineral density below million osteoporotic fractures per year, annual direct cost of $18B (373K stroke, 345K MI, 216K Breast CA) < 25% of women who sustain an osteoporotic fracture currently receive appropriate treatment

10-Year Probability of any Fracture in Untreated Postmenopausal Women* AGE T-Score National Osteoporosis Foundation *Note: other independent risk factors for fracture will increase fracture risk

Decision to treat?  At present, no national guidelines regarding the absolute threshold at which pharmacologic therapy should be instituted  Osteoporosis therapy can reduce the risk of fracture by as much as 50%, but some women have fractures despite treatment  Changes in lifestyle, compliance with medication regimen, as well as cost ($70/mo), are lifetime commitments  A substantial percentage of fractures occur in women who have osteopenia, not osteoporosis

Treatment Decisions  Everyone Maintain adequate calcium intake Adopt good general nutrition Ensure adequate vitamin D intake Engage in regular weight-bearing exercise Avoid use of tobacco  Nonpharmacologic options  Pharmacologic options Any postmenopausal woman with prior spine/hip fracture

Nonpharmacologic options  Calcium + Vitamin D Combined: slow bone loss, enhance the effect of pharmacologic therapy, reduce hip/nonvertebral fractures Additional Vitamin D: significantly increased muscle strength, reduced body sway, and resulted in fewer falls “Calcium has been singled out as a major public health concern today because it is critical to bone health and the average American consumes levels of calcium that are far below the amount recommended for optimal bone health” – HHS, OTSG, 2004  Calcium: 1200mg/day divided into 600mg doses  Vitamin D: 400 IU, although suggested higher intake ( ) General agreement that exercise important for bone health

Pharmacologic therapy  SERM (Raloxifene 60mg/d) Reduced vertebral fractures, no effect on hip  Calcitonin (Nasal Spray 200 IU/d) Reduced vertebral fractures, no effect on hip  Bisphosphonates (Alendronate 70mg/wk treatment or 35mg/wk prevention, Risedronate 35mg/wk, or Ibandronate 150mg/mo) Reduced hip and vertebral fractures, ibandronate not hip  Estrogen/Estrogen plus progestin Reduced vertebral, wrist, and hip fractures  Anabolic therapy (Teriparatide [PTH] 20mcg/d) Reduced vertebral and nonvertebral fractures

What Do You Do With Osteopenia? -2.5 or below or fracture STOP (red light) High Risk Treat -1.5 to -2.5Caution (yellow light) Consider therapy if other risk factors of fracture Above -1.5OK (green light) Low risk General preventation Summary of treatment decisions for postmenopausal women based on risk factors for osteoporotic fracture (American Association of Clinical Endocrinologists Guidelines)

Osteopenia anyone? Anyone?  Women with a T-score between -1.5 and -2.5 may be treated, depending on their calculated fracture risk based on age, BMD, and the presence of other independent risk factors (National Osteoporosis Foundation)  Everyone with osteopenia (-1.0 to -2.5) or osteoporosis gets the treatment dosage of bisphosphonates (personal communication with Dr. Wood, DDEAMC Endocrinologist)

10-Year Probability AGE T-Score

BMD Test Reimbursement  The Bone Mass Measurement Act (Medicare) Estrogen-deficient women at risk for osteoporosis Vertebral anomalies Chronic glucocorticoid therapy* Primary hyperparathyroidism Assess response to, or efficacy of, FDA-approved osteoporosis drug  Covered by Medicare every 23 months*